Partner Courtenay Brinckerhoff was quoted in a BioWorld article, “With BPCIA Dance Optional, Next Moves Up to Biosimilar Sponsors,” on July 24, 2015. The article discussed next steps for biosimilar sponsors after the Federal Circuit confirmed that the Biologic Price Competition and Innovation Act’s intricate patent information exchange is optional. Brinckerhoff said it’s likely that many biosimilar developers will choose not to follow the steps in place by BPCIA since it requires the biosimilar sponsor to give a copy of its application and other confidential manufacturing-related information to the reigning market champion.
People
Related News
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."
August 5, 2025
In the News
Aaron Maguregui on Health Data Sharing Plan – 'I would expect the FTC to be heavily involved'
Foley & Lardner LLP partner Aaron Maguregui addressed a new health care data sharing initiative announced by the federal government in the Bloomberg Law article, "Digital Data-Sharing Plan Tests Limits of Health Privacy Rules."